M3 Group Joins MEDIROM Mother Labs’ Series A Financing Round at JPY9 Billion (as of December 1, 2024, approximately USD $59,000,000) Pre-Money Valuation
2024年12月3日 - 6:00AM
MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (“MEDIROM”)
announces that M3, Inc. (TOKYO PRIME: 2413), or an affiliate within
the M3 group, is participating in the Series A equity financing
round of MEDIROM MOTHER Labs Inc., a subsidiary of MEDIROM. NFES
Technologies Inc. is the lead investor of the Series A financing
round at a pre-money valuation of JPY9 billion. Additional
information is available here:
https://medirom.co.jp/en/ir/20240824/6148%09
Forward-Looking Statements Regarding
MEDIROM
Certain statements in this press release are
forward-looking statements for purposes of the safe harbor
provisions under the U.S. Private Securities Litigation Reform Act
of 1995. Forward-looking statements may include estimates or
expectations about MEDIROM’s possible or assumed operational
results, financial condition, business strategies and plans, market
opportunities, competitive position, industry environment, and
potential growth opportunities. In some cases, forward-looking
statements can be identified by terms such as “may,” “will,”
“should,” “design,” “target,” “aim,” “hope,” “expect,” “could,”
“intend,” “plan,” “anticipate,” “estimate,” “believe,” “continue,”
“predict,” “project,” “potential,” “goal,” or other words that
convey the uncertainty of future events or outcomes. These
statements relate to future events or to MEDIROM’s future financial
performance, and involve known and unknown risks, uncertainties and
other factors that may cause MEDIROM’s actual results, levels of
activity, performance, or achievements to be different from any
future results, levels of activity, performance or achievements
expressed or implied by these forward-looking statements. You
should not place undue reliance on forward-looking statements
because they involve known and unknown risks, uncertainties and
other factors which are, in some cases, beyond MEDIROM’s control
and which could, and likely will, affect actual results, levels of
activity, performance or achievements. Any forward-looking
statement reflects MEDIROM’s current views with respect to future
events and is subject to these and other risks, uncertainties and
assumptions relating to MEDIROM’s operations, results of
operations, growth strategy and liquidity.
More information on these risks and other
potential factors that could affect MEDIROM’s business, reputation,
results of operations, financial condition, and stock price is
included in MEDIROM’s filings with the Securities and Exchange
Commission (the “SEC”), including in the “Risk Factors” and
“Operating and Financial Review and Prospects” sections of
MEDIROM’s most recently filed periodic report on Form 20-F and
subsequent filings, which are available on the SEC website at
www.sec.gov. MEDIROM assumes no obligation to update or revise
these forward-looking statements for any reason, or to update the
reasons actual results could differ from those anticipated in these
forward-looking statements, even if new information becomes
available in the future.
ABOUT M3, Inc.M3 is a one of a kind venture
company that operates a multitude of global services centred around
its physician platform such as m3.com.M3 is the first company
incorporated after the year 2000 to be included in the Nikkei 225
Index. Its 330,000+ Japanese and 6,500,000+ global physician member
panel serves as a central platform in advancing innovation and
reform across healthcare worldwide.
Tokyo Stock Exchange Prime Market (Securities code 2413)1-11-44
Akasaka Minato-ku, Tokyo 107-0052
JAPANWeb https://corporate.m3.com/en
ABOUT MEDIROM MOTHER Labs Inc.A subsidiary of
MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM), focuses on the
health-tech sector. The company’s core activities include the
"Specific Health Guidance Program" offered through the "Lav" health
application and development and sales of the 24/7 recharge-free
MOTHER Bracelet smart tracker. By leveraging the features of the
recharge-free MOTHER Bracelet, MOTHER Labs offers customizable
health management solutions across diverse sectors, including
caregiving, logistics, manufacturing, etc.
MEDIROM Healthcare Technologies Inc.NASDAQ
Symbol: MRMTradepia Odaiba, 2-3-1 Daiba, Minato-ku, Tokyo, JapanWeb
https://medirom.co.jp/enContact: ir@medirom.co.jp
MEDIROM MOTHER Labs Inc.Tradepia Odaiba, 2-3-1
Daiba, Minato-ku, Tokyo, Japan
MOTHER Bracelet is the world's first* 24/7 recharge-free smart
tracker. It uses innovative technology from a Silicon Valley tech
company that allows for power generation based on temperature
differences between body and surrounding air. The recharge-free
feature eliminates the risk of data loss when a device is taken off
for recharge. MOTHER Bracelet records five basic metrics: heart
rate, calories burned, body surface temperature, step count, and
sleep. Official Website: https://mother-bracelet.com
MEDIROM Healthcare Techn... (NASDAQ:MRM)
過去 株価チャート
から 11 2024 まで 12 2024
MEDIROM Healthcare Techn... (NASDAQ:MRM)
過去 株価チャート
から 12 2023 まで 12 2024